
The company reported third-quarter net profit of €184.5 million and lifted its full-year revenue target despite lower sales.
BioNTech returned to profit in the third quarter, reporting net income of €184.5 million for July through September. A year earlier, it recorded a net loss of €28.7 million.
Earnings per share increased to €0.73 from €0.12. The company’s return to profit was mainly due to large one-off expenses tied to lawsuits and legal disputes not recurring this year, according to the reports.
Revenue fell to €1.29 billion from €1.52 billion a year earlier as global demand for COVID-19 vaccines continued to decline. BioNTech nevertheless raised its 2026 revenue target range to €1.7 billion to €1.9 billion, lifting the lower end from at least €1.6 billion.
The company said it was accelerating its shift toward cancer medicines as it seeks to reduce its dependence on the shrinking COVID-19 vaccine market. It aims to bring more than one oncology product to market by 2030.
Research and development expenses rose to €748.1 million in the quarter, from €564.8 million a year earlier, amid the strategic shift and ongoing clinical studies. As of Tuesday afternoon, BioNTech shares traded at $87.56, up 0.03% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.